0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
From the Centers for Disease Control and Prevention |

Update: Severe Acute Respiratory Syndrome—United States, May 28, 2003 FREE

JAMA. 2003;289(24):3231. doi:10.1001/jama.289.24.3231-a.
Text Size: A A A
Published online

UPDATE: SEVERE ACUTE RESPIRATORY SYNDROME—UNITED STATES, MAY 28, 2003

MMWR. 2003;52:500-501

1 table, 1 figure omitted

CDC continues to work with state and local health departments, the World Health Organization (WHO), and other partners to investigate cases of severe acute respiratory syndrome (SARS). This report updates SARS cases reported worldwide and in the United States and reports a seventh laboratory-confirmed U.S. case.

During November 1, 2002–May 28, 2003, a total of 8,240 SARS cases were reported to WHO from 28 countries, including the United States; 745 deaths (case-fatality proportion: 9.0%) have been reported.1 The 363 SARS cases identified in the United States have been reported from 41 states and Puerto Rico, with 297 (82%) cases classified as suspect SARS and 66 (18%) classified as probable SARS (more severe illnesses characterized by the presence of pneumonia or acute respiratory distress syndrome).2 Of the 66 probable SARS patients, 43 (65%) were hospitalized, and two (3%) required mechanical ventilation. No SARS-related deaths have been reported in the United States. Of 66 probable cases, 64 (97%) were attributed to international travel to areas with documented or suspected community transmission of SARS within the 10 days before illness onset; the remaining two (3%) probable cases occurred in a health-care worker who provided care to a SARS patient and a household contact of a SARS patient. Since the last update, new cases of SARS have been reported in Toronto, Canada, and CDC has reissued a travel alert for Toronto.3 Consequently, the surveillance case definition continues to include cases in persons whose illness is consistent with the clinical criteria and began within 10 days of travel to Toronto.2

Serologic testing for antibody to SARS-associated coronavirus (SARS-CoV) has been performed for 32 (48%) probable cases and was positive for seven, six of which have been described previously as laboratory-confirmed cases. For one patient, a reverse transcriptase polymerase chain reaction (RT-PCR) assay detected SARS-CoV ribonucleic acid in a sputum specimen collected 14 days after illness onset4,5; this patient subsequently had antibody to SARS-CoV. The seventh patient, a household contact of one of the six patients with positive serology, was reported previously as a probable SARS patient on the basis of clinical and epidemiologic criteria.4 Among the seven patients, four had positive serology on or before day 12 after onset of symptoms. The other three had negative serologic tests on day 4, 6, and 14, respectively, and a positive test in the next available serum sample on day 28, 25, and 41, respectively. Serologic testing has been performed for 111 (37%) suspect cases; antibody was not detected for any of those tested.

CDC measures SARS-CoV–specific total IgG, IgM, and IgA antibodies by both enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence antibody (IFA).6 A serum specimen is reported as positive when both tests are positive. Antibodies against other human and nonhuman coronaviruses do not react in these assays, and tests on sera from 384 persons without SARS-CoV infection all were negative. These findings indicate that SARS-CoV has emerged recently within the population and that the serologic methods are specific for detection of antibody against SARS-CoV and have a low false-positive rate.

Rapid identification of SARS-CoV as the etiologic agent of SARS and extensive international collaboration has aided in the development of this diagnostic test. Of the 66 probable SARS cases, convalescent serum has been collected for 40 (61%). Testing of convalescent serum is invaluable in confirming infection with SARS-CoV, and every effort should be made to obtain follow-up specimens >21 days after onset of illness.

Reported by:

State and local health departments. SARS Investigative Team, CDC.

References
World Health Organization.  Cumulative number of reported cases of severe acute respiratory syndrome (SARS). Available at http://www.who.int/csr/sars/country/2003_05_28/en.
CDC.  Updated interim U.S. case definition of severe acute respiratory syndrome (SARS). Available at http://www.cdc.gov/ncidod/sars/casedefinition.htm.
CDC.  Travel alert reinstated: Toronto, Ontario, Canada. Available at http://www.cdc.gov/travel/other/sars_can.htm.
CDC.  Severe acute respiratory syndrome (SARS) and coronavirus testing—United States, 2003.  MMWR.2003;52:297-302.
CDC.  Update: severe acute respiratory syndrome—United States, 2003.  MMWR.2003;52:357-60.
Ksiazek TG, Erdman D, Goldsmith CS.  et al.  A novel coronavirus associated with severe acute respiratory syndrome.  N Engl J Med.2003;348:1953-66.

Figures

Tables

References

World Health Organization.  Cumulative number of reported cases of severe acute respiratory syndrome (SARS). Available at http://www.who.int/csr/sars/country/2003_05_28/en.
CDC.  Updated interim U.S. case definition of severe acute respiratory syndrome (SARS). Available at http://www.cdc.gov/ncidod/sars/casedefinition.htm.
CDC.  Travel alert reinstated: Toronto, Ontario, Canada. Available at http://www.cdc.gov/travel/other/sars_can.htm.
CDC.  Severe acute respiratory syndrome (SARS) and coronavirus testing—United States, 2003.  MMWR.2003;52:297-302.
CDC.  Update: severe acute respiratory syndrome—United States, 2003.  MMWR.2003;52:357-60.
Ksiazek TG, Erdman D, Goldsmith CS.  et al.  A novel coronavirus associated with severe acute respiratory syndrome.  N Engl J Med.2003;348:1953-66.
CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles